{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T13:24:30Z","timestamp":1787145870274,"version":"build-2736575974"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,19]]},"DOI":"10.7759\/cureus.114782","type":"journal-article","created":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T12:34:28Z","timestamp":1787142868000},"source":"Crossref","is-referenced-by-count":0,"title":["A Novel Approach to Managing \u201cDouble Diabetes\u201d in a Pediatric Patient on Insulin Pump Therapy: An Off-Label Use of a Fixed-Ratio Insulin Degludec\/Liraglutide Combination"],"prefix":"10.7759","author":[{"given":"Batool","family":"Almoallem","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nandu K","family":"Thalange","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-024-02145-x","article-title":"Double diabetes-when type 1 diabetes meets type 2 diabetes: definition, pathogenesis and recognition","volume":"23","author":"Bielka W","year":"2024","unstructured":"Bielka W, Przezak A, Mol\u0119da P, Pius-Sadowska E, Machali\u0144ski B. Double diabetes-when type 1 diabetes meets type 2 diabetes: definition, pathogenesis and recognition. Cardiovasc Diabetol. 2024, 23:62. 10.1186\/s12933-024-02145-x","journal-title":"Cardiovasc Diabetol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2016.06.003","article-title":"Prevalence and comorbidities of double diabetes","volume":"119","author":"Merger SR","year":"2016","unstructured":"Merger SR, Kerner W, Stadler M, Zeyfang A, Jehle P, M\u00fcller-Korbsch M, Holl RW. Prevalence and comorbidities of double diabetes. Diabetes Res Clin Pract. 2016, 119:48-56. 10.1016\/j.diabres.2016.06.003","journal-title":"Diabetes Res Clin Pract"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.tem.2006.12.003","article-title":"A new expression of diabetes: double diabetes","volume":"18","author":"Pozzilli P","year":"2007","unstructured":"Pozzilli P, Buzzetti R. A new expression of diabetes: double diabetes. Trends Endocrinol Metab. 2007, 18:52-7. 10.1016\/j.tem.2006.12.003","journal-title":"Trends Endocrinol Metab"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.eprac.2023.10.134","article-title":"Children and adolescents with hybrid diabetes: a management conundrum","volume":"30","author":"Gagnon CA","year":"2024","unstructured":"Gagnon CA, Schmitt JA, Ashraf AP. Children and adolescents with hybrid diabetes: a management conundrum. Endocr Pract. 2024, 30:49-56. 10.1016\/j.eprac.2023.10.134","journal-title":"Endocr Pract"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2017.01.012","article-title":"Correlates of overweight and obesity in 5529 adolescents with type 1 diabetes: the T1D Exchange Clinic Registry","volume":"126","author":"Minges KE","year":"2017","unstructured":"Minges KE, Whittemore R, Weinzimer SA, Irwin ML, Redeker NS, Grey M. Correlates of overweight and obesity in 5529 adolescents with type 1 diabetes: the T1D Exchange Clinic Registry. Diabetes Res Clin Pract. 2017, 126:68-78. 10.1016\/j.diabres.2017.01.012","journal-title":"Diabetes Res Clin Pract"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-013-2904-2","article-title":"Insulin resistance in type 1 diabetes: what is 'double diabetes' and what are the risks?","volume":"56","author":"Cleland SJ","year":"2013","unstructured":"Cleland SJ, Fisher BM, Colhoun HM, Sattar N, Petrie JR. Insulin resistance in type 1 diabetes: what is 'double diabetes' and what are the risks?. Diabetologia. 2013, 56:1462-70. 10.1007\/s00125-013-2904-2","journal-title":"Diabetologia"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3390\/children8080710","article-title":"Acanthosis nigricans in children and adolescents with type 1 diabetes or obesity: the potential interplay role between insulin resistance and excess weight","volume":"8","author":"Calcaterra V","year":"2021","unstructured":"Calcaterra V, De Silvestri A, Schneider L, et al.. Acanthosis nigricans in children and adolescents with type 1 diabetes or obesity: the potential interplay role between insulin resistance and excess weight. Children (Basel). 2021, 8:710. 10.3390\/children8080710","journal-title":"Children (Basel)"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.2165\/00128071-200405030-00008","article-title":"Acanthosis nigricans associated with insulin resistance: pathophysiology and management","volume":"5","author":"Hermanns-L\u00ea T","year":"2004","unstructured":"Hermanns-L\u00ea T, Scheen A, Pi\u00e9rard GE. Acanthosis nigricans associated with insulin resistance: pathophysiology and management. Am J Clin Dermatol. 2004, 5:199-203. 10.2165\/00128071-200405030-00008","journal-title":"Am J Clin Dermatol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3389\/fcdhc.2024.1530811","article-title":"GLP-1 receptor agonists in diabetes and weight loss: the double-edged sword of innovation and risks","volume":"5","author":"Ilias I","year":"2024","unstructured":"Ilias I, Zabuliene L, Rizzo M. GLP-1 receptor agonists in diabetes and weight loss: the double-edged sword of innovation and risks. Front Clin Diabetes Healthc. 2024, 5:1530811. 10.3389\/fcdhc.2024.1530811","journal-title":"Front Clin Diabetes Healthc"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.2337\/dc16-0691","article-title":"Efficacy and safety of liraglutide added to insulin treatment in type 1 diabetes: the adjunct one treat-to-target randomized trial","volume":"39","author":"Mathieu C","year":"2016","unstructured":"Mathieu C, Zinman B, Hemmingsson JU, et al.. Efficacy and safety of liraglutide added to insulin treatment in type 1 diabetes: the adjunct one treat-to-target randomized trial. Diabetes Care. 2016, 39:1702-10. 10.2337\/dc16-0691","journal-title":"Diabetes Care"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.2337\/dc16-0690","article-title":"Efficacy and safety of liraglutide added to capped insulin treatment in subjects with type 1 diabetes: the adjunct two randomized trial","volume":"39","author":"Ahr\u00e9n B","year":"2016","unstructured":"Ahr\u00e9n B, Hirsch IB, Pieber TR, et al.. Efficacy and safety of liraglutide added to capped insulin treatment in subjects with type 1 diabetes: the adjunct two randomized trial. Diabetes Care. 2016, 39:1693-701. 10.2337\/dc16-0690","journal-title":"Diabetes Care"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(15)00436-2","article-title":"Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): a randomised, double-blind, placebo-controlled trial","volume":"4","author":"Dejgaard TF","year":"2016","unstructured":"Dejgaard TF, Frandsen CS, Hansen TS, et al.. Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2016, 4:221-32. 10.1016\/S2213-8587(15)00436-2","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1159\/000541228","article-title":"Use of GLP-1 receptor agonists for the management of type 1 diabetes: a pediatric perspective","volume":"98","author":"Shenker MN","year":"2025","unstructured":"Shenker MN, Shalitin S. Use of GLP-1 receptor agonists for the management of type 1 diabetes: a pediatric perspective. Horm Res Paediatr. 2025, 98:405-24. 10.1159\/000541228","journal-title":"Horm Res Paediatr"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2024.0328","article-title":"Effectiveness of semaglutide and tirzepatide in overweight and obese adults with type 1 diabetes","volume":"27","author":"Snell-Bergeon JK","year":"2025","unstructured":"Snell-Bergeon JK, Kaur G, Renner D, Akturk HK, Beatson C, Garg SK. Effectiveness of semaglutide and tirzepatide in overweight and obese adults with type 1 diabetes. Diabetes Technol Ther. 2025, 27:1-9. 10.1089\/dia.2024.0328","journal-title":"Diabetes Technol Ther"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/519363-a-novel-approach-to-managing-double-diabetes-in-a-pediatric-patient-on-insulin-pump-therapy-an-off-label-use-of-a-fixed-ratio-insulin-degludecliraglutide-combination","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T12:34:31Z","timestamp":1787142871000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/519363-a-novel-approach-to-managing-double-diabetes-in-a-pediatric-patient-on-insulin-pump-therapy-an-off-label-use-of-a-fixed-ratio-insulin-degludecliraglutide-combination"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,19]]},"references-count":14,"URL":"https:\/\/doi.org\/10.7759\/cureus.114782","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8,19]]}}}